Document is current
Any future updates will be listed below
-
Authors
Schultz, Liora
McNerney, Kevin
Lamble, Adam J.
Calkoen, Friso G.
Baruchel, Andre
Ceppi, Francesco
Curran, Kevin J.
Gore, Lia
Lamb, Margaret https://orcid.org/0000-0001-9413-3637
Maude, Shannon L.
Pulsipher, Michael A.
Qayed, Muna
Ramakrishna, Sneha
Rheingold, Susan R.
Rossig, Claudia
Silbert, Sara K.
Steineck, Angela https://orcid.org/0000-0002-8000-0179
Summers, Corinne
Capitini, Christian M. https://orcid.org/0000-0002-2276-6731
Bhojwani, Deepa
Gardner, Rebecca A.
Ghorashian, Sara
Shah, Nirali N. https://orcid.org/0000-0002-8474-9080
- License Information
-
More Information
Article History
Accepted: 15 December 2025
First Online: 23 January 2026
Competing interests
: L.G. has received travel funding and honoraria from Amgen. S.L.M. has received research support for clinical trials sponsored by Luminary Therapeutics. M.A.P. has served on advisory boards for Autolus, bluebird bio, Cargo Therapeutics, Garuda/Stratus Therapeutics, GentiBio, Mesoblast, Novartis and Pfizer; and had received research support from Adaptive Biotech and Miltenyi Biotec. M.Q. has received honoraria from Medexus. S.R.R. declares consultancy roles for Amgen and Pfizer. C.R. has received honoraria from Amgen and Novartis. C.M.C. reports honoraria from Bayer, Nektar Therapeutics and Novartis; and has equity interest in Elephas. D.B. declares research funding from Wugen. R.A.G. has patents related to CAR T cell technologies licensed with royalties paid from Juno Therapeutics. N.N.S. declares research funding from Cargo Therapeutics, Lentigen and Vor Bio; has attended advisory board meetings (no honoraria) for ImmunoACT, Sobi and Vor Bio; and receives royalties from Cargo Therapeutics. The other authors declare no competing interests.
